Literature DB >> 7908682

Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.

G F Murphy1, H Sueki, C Teuscher, D Whitaker, R Korngold.   

Abstract

The skin is a major target organ for graft-versus-host disease (GVHD), the principal complication of allogeneic bone marrow transplantation. The purpose of the present study was to test whether mast cell degranulation might be related to early target cell injury in the development of acute GVHD. We employed two irradiated murine strain combinations, one in which disease was mediated by CD4+ effector T cells (B10.D2-->DBA/2), and the other by CD8+ effector T cells (B10.BR-->CBA). As compared to controls, both models exhibited mast cell degranulation of differing extents and patterns, as well as dyskeratosis in the epidermis before the influx of effector lymphocytes. These results suggested that factors produced and released by degranulated dermal mast cells might contribute to early target cell injury. Accordingly, the possible role of tumor necrosis factor (TNF)-alpha, a cytokine recently discovered in mast cell granules, was investigated by the injection of anti-TNF-alpha antibody during the course of disease mediated by either CD4+ or CD8+ T cells. Although overall survival of recipients undergoing CD4+ T-cell-mediated GVHD was only slightly improved and the extent of mast cell degranulation was not affected by anti-TNF-alpha antibody treatment, the skin exhibited a significant diminution in the number of dyskeratotic cells/linear mm at 3-4 weeks post-transplantation. In contrast, anti-TNF-alpha antibody failed to enhance survival or reduce the number of dyskeratotic cells in the skin during CD8+ T-cell-mediated disease. Finally, to determine whether CD8+ T-cell-mediated GVHD was at all dependent upon mast cell involvement, the C3H.SW-->B6WWv strain combination was utilized, in which recipients were genetically deficient in mast cells. Onset of GVHD was significantly delayed in B6WWv mice and was clearly correlated to the appearance and increase of de novo mast cells at later time points.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908682     DOI: 10.1111/1523-1747.ep12373016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.

Authors:  Jenny Zilberberg; Danielle McElhaugh; Loise N Gichuru; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

Review 2.  Regulatory roles of mast cells in immune responses.

Authors:  Hideaki Morita; Hirohisa Saito; Kenji Matsumoto; Susumu Nakae
Journal:  Semin Immunopathol       Date:  2016-05-06       Impact factor: 9.623

3.  Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality.

Authors:  Celalettin Ustun; Todd E DeFor; Fatma K Karadag; Hyun Don Yun; Sunita Nathan; Claudio G Brunstein; Bruce R Blazar; Daniel J Weisdorf; Shernan G Holtan; Khalid Amin
Journal:  Blood Adv       Date:  2020-05-26

4.  Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease.

Authors:  Isao Tawara; Evelyn Nieves; Chen Liu; Rebecca Evers; Tomomi Toubai; Yaping Sun; Mariem Alrubaie; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-25       Impact factor: 5.742

5.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.

Authors:  Stephen C Jones; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 6.  Mast cells and immunological skin diseases.

Authors:  Daniel Navi; Jun Saegusa; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 7.  Target cells in graft-versus-host disease: implications for cancer therapy.

Authors:  George F Murphy
Journal:  Clin Rev Allergy Immunol       Date:  2007-08-14       Impact factor: 8.667

8.  Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.

Authors:  Dennis B Leveson-Gower; Emanuela I Sega; Janet Kalesnikoff; Mareike Florek; Yuqiong Pan; Antonio Pierini; Stephen J Galli; Robert S Negrin
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.

Authors:  Acf Motta; Q Zhan; A Larson; M Lerman; S-B Woo; R J Soiffer; G F Murphy; N S Treister
Journal:  Oral Dis       Date:  2018-03-13       Impact factor: 3.511

10.  Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease.

Authors:  Judith C Kim; Diana Whitaker-Menezes; Masatoshi Deguchi; Brigette S Adair; Robert Korngold; George F Murphy
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.